Medivation, Inc. is a biopharmaceutical company focused on the rapid development of novel small molecule drugs to treat critically ill patients with serious diseases for which there are limited treatment options. Medivation aims to transform the treatment of these diseases and offer hope to critically ill patients and their caregivers.
Dimebon (latrepirdine) is an investigational drug candidate for the treatment of Alzheimer’s disease.About Alzheimer's DiseaseAlzheimer’s disease is a progressive degenerative brain disorder that gradually destroys a person’s memory and ability to learn, reason, make judgments, communicate and carry out daily activities. As the disease progresses, patients may experience changes in personality and behavior, and suffer from anxiety, agitation, delusions or hallucinations. Alzheimer’s disease is the most common dementia among older adults. In the United States, more than 5 million people suffer from Alzheimer’s disease, with that number expected to grow to 14 million by 2050. Five drugs, with combined sales of approximately $5 billion, are approved in the U.S. to treat Alzheimer’s disease. However, these drugs have modest effect and are not believed to modify the underlying disease. There remains a significant unmet medical need in Alzheimer’s disease. |
 |
 |
| Medivation © 2010 |